Cancer Biology & Medicine最新文献

{"title":"Azoximer bromide and hydroxyapatite: promising immune adjuvants in cancer.","authors":"Jean-François Rossi, Patrick Frayssinet, Maksim Matciyak, Nikolai Tupitsyn","doi":"10.20892/j.issn.2095-3941.2023.0222","DOIUrl":"10.20892/j.issn.2095-3941.2023.0222","url":null,"abstract":"<p><p>Immune adjuvants are immune modulators that have been developed in the context of infectious vaccinations. There is currently a growing interest in immune adjuvants due to the development of immunotherapy against cancers. Immune adjuvant mechanisms of action are focused on the initiation and amplification of the inflammatory response leading to the innate immune response, followed by the adaptive immune response. The main activity lies in the support of antigen presentation and the maturation and functions of dendritic cells. Most immune adjuvants are associated with a vaccine or incorporated into the new generation of mRNA vaccines. Few immune adjuvants are used as drugs. Hydroxyapatite (HA) ceramics and azoximer bromide (AZB) are overlooked molecules that were used in early clinical trials, which demonstrated clinical efficacy and excellent tolerance profiles. HA combined in an autologous vaccine was previously developed in the veterinary field for use in canine spontaneous lymphomas. AZB, an original immune modulator derived from a class of heterochain aliphatic polyamines that is licensed in Russia, the Commonwealth of Independent States, and Slovakia for infectious and inflammatory diseases, is and now being developed for use in cancer with promising results. These two immune adjuvants can be combined in various immunotherapy strategies.</p>","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":"20 12","pages":""},"PeriodicalIF":5.5,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10845929/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139691284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnosis of malnutrition in cancer patients.","authors":"Chunhua Song, Hanping Shi","doi":"10.20892/j.issn.2095-3941.2023.0473","DOIUrl":"10.20892/j.issn.2095-3941.2023.0473","url":null,"abstract":"","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":"20 12","pages":""},"PeriodicalIF":5.5,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10845926/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139691288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Precision medicine in the treatment of colorectal cancer with liver metastases.","authors":"Yuqiu Xu, Yang Lv, Zhehui Zhu, Yijiao Chen, Peiwen Zhou, Lechi Ye, Wentao Tang, Jianmin Xu","doi":"10.20892/j.issn.2095-3941.2023.0483","DOIUrl":"10.20892/j.issn.2095-3941.2023.0483","url":null,"abstract":"","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":"20 12","pages":""},"PeriodicalIF":5.5,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10845938/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139691296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolic regulation of innate immunity in cancer immunotherapy.","authors":"Yuheng Liao, Hui Yang","doi":"10.20892/j.issn.2095-3941.2024.0022","DOIUrl":"10.20892/j.issn.2095-3941.2024.0022","url":null,"abstract":"","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":"20 12","pages":""},"PeriodicalIF":5.5,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10845941/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139691293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Road of no return - loss of TP53 paves a defined evolution path from gastric preneoplasia-to-cancer.","authors":"Liwei An, Yi Han, Shi Jiao, Zhaocai Zhou","doi":"10.20892/j.issn.2095-3941.2023.0435","DOIUrl":"10.20892/j.issn.2095-3941.2023.0435","url":null,"abstract":"","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":"20 12","pages":""},"PeriodicalIF":5.5,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10845934/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139691298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nodal peripheral T-cell lymphomas in the new classification systems.","authors":"Catalina Amador, Wing C Chan","doi":"10.20892/j.issn.2095-3941.2023.0490","DOIUrl":"10.20892/j.issn.2095-3941.2023.0490","url":null,"abstract":"","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":"20 12","pages":""},"PeriodicalIF":5.5,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10845937/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139691295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world effectiveness and safety of goserelin 10.8-mg depot in Chinese patients with localized or locally advanced prostate cancer.","authors":"Nanhui Chen, Zengjun Wang, Ming Chen, Qi Ma, Yi He, Yujie Wang, Xin Li, Mingxing Qiu, Lei Shi, Shaoxing Zhu, Qun Xie, Xiuheng Liu, Benkang Shi, Guowen Lin, Weizhong Yang, Yongbin Liao, Haibin Zhang, Shusheng Wang, Jiexian Li, Shaogang Wang, Lijun Dong, Hui Chen, Jiaju Lu, Yongyi Cheng, Xiaoping Zhang, Lulin Ma, Liqun Zhou, He Wang, Shen Li, Dingwei Ye","doi":"10.20892/j.issn.2095-3941.2023.0335","DOIUrl":"10.20892/j.issn.2095-3941.2023.0335","url":null,"abstract":"<p><strong>Objective: </strong>Real-word data on long-acting luteinizing hormone-releasing hormone (LHRH) agonists in Chinese patients with prostate cancer are limited. This study aimed to determine the real-world effectiveness and safety of the LHRH agonist, goserelin, particularly the long-acting 10.8-mg depot formulation, and the follow-up patterns among Chinese prostate cancer patients.</p><p><strong>Methods: </strong>This was a multicenter, prospective, observational study in hormone treatment-naïve patients with localized or locally advanced prostate cancer who were prescribed goserelin 10.8-mg depot every 12 weeks or 3.6-mg depot every 4 weeks with or without an anti-androgen. The patients had follow-up evaluations for 26 weeks. The primary outcome was the effectiveness of goserelin in reducing serum testosterone and prostate-specific antigen (PSA) levels. The secondary outcomes included testosterone and PSA levels, attainment of chemical castration (serum testosterone <50 ng/dL), and goserelin safety. The exploratory outcome was the monitoring pattern for serum testosterone and PSA. All analyses were descriptive.</p><p><strong>Results: </strong>Between September 2017 and December 2019, a total of 294 eligible patients received ≥ 1 dose of goserelin; 287 patients (97.6%) were treated with goserelin 10.8-mg depot. At week 24 ± 2, the changes from baseline [standard deviation (95% confidence interval)] in serum testosterone (<i>n</i> = 99) and PSA (<i>n</i> = 131) were -401.0 ng/dL [308.4 ng/dL (-462.5, -339.5 ng/dL)] and -35.4 ng/mL [104.4 ng/mL (-53.5, -17.4 ng/mL)], respectively. Of 112 evaluable patients, 100 (90.2%) achieved a serum testosterone level < 50 ng/dL. Treatment-emergent adverse events (TEAEs) and severe TEAEs occurred in 37.1% and 10.2% of patients, respectively. The mean testing frequency (standard deviation) was 1.6 (1.5) for testosterone and 2.2 (1.6) for PSA.</p><p><strong>Conclusions: </strong>Goserelin 10.8-mg depot effectively achieved and maintained castration and was well-tolerated in Chinese patients with localized and locally advanced prostate cancer.</p>","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":"20 12","pages":""},"PeriodicalIF":5.5,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10845927/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139691297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment strategies for patients with HER2-positive gastric cancer.","authors":"Feixue Wang, Yi Ba","doi":"10.20892/j.issn.2095-3941.2023.0480","DOIUrl":"10.20892/j.issn.2095-3941.2023.0480","url":null,"abstract":"","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":"20 12","pages":""},"PeriodicalIF":5.5,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10845943/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139691314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug clinical trials on high-grade gliomas: challenges and hopes.","authors":"Mengqian Huang, Shenglan Li, Parker Li, Zhuang Kang, Botao Zhang, Wenbin Li","doi":"10.20892/j.issn.2095-3941.2023.0364","DOIUrl":"10.20892/j.issn.2095-3941.2023.0364","url":null,"abstract":"","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":"20 12","pages":""},"PeriodicalIF":5.5,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10845939/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139691290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DNA methylation biomarkers for early detection of gastric and colorectal cancers.","authors":"Xianchun Gao, Hui Liu, Jun Yu, Yongzhan Nie","doi":"10.20892/j.issn.2095-3941.2023.0443","DOIUrl":"10.20892/j.issn.2095-3941.2023.0443","url":null,"abstract":"","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":"20 12","pages":""},"PeriodicalIF":5.5,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10845933/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139691289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}